Member Info for TonyFawcett

There is a worldwide shortage of Antibodies and they take a longer time to produce as well as not being that accurate. Affirmer platform antigens are quicker to produce and more accurate, plus more applications, especially in Cancer Therepy which long term will be more profitable. In the shorter term , well we are watching and waiting on how our response to CV-19 develops.

Gold holds on to Friday’s rally and looking for another move upwards this morning.

It would have to be in the region of £20 per share, in fairness it is probably worth at least that. But it will need a big player to get the most out of the science. What’s the world economy worth ? You can’t put a price on people’s lives.

To be fair AVCT is undervalued on its cancer treatment science never mind CV-19 .

We are all being sucked in at the moment with the euphoria and wild speculation of future valuations. We are all rainbow hunters ramping up speculation on what is at the moment Jam tomorrow, I am not selling, I have fallen for all the hype. There is lots of talk about what is going to be a new normal for at least the next few years and I believe with a fair wind it will be good for the shareholders as well as the people on the planet and the worlds economy. I do believe that AVCT have an edge with their science. I am worried that a takeover might undervalue the company and its prospects. But if this science can restore the world to what it was with better ideals and a more considerate society is more important than lining investors pockets.

There’s nothing wrong with taking a profit , Rothschild made his money by selling too early .

The very fact that the new normal will require rapid testing on a massive scale , laboratory testing is not adequate or what is needed to lift the lockdown even with restrictions. In order for the economy to start to recover rapid testing on mass scale worldwide is going to be necessary. The fact that AVCT have also the science to block and treat CV-19 patients has not been yet appreciated in the SP. I know it all sounds like Jam tomorrow the SP is bargain basement to what it might go to in the coming days, weeks and months ahead. As FDA and CE approval is only weeks away I think the news flow will further lift the SP.
I also like the look of Open Orphan (ORPH) who as a service company to the pharma industry and a beneficiary of the Covid-19 outbreak.

Gold prices shot up on Friday , if the rally continues with the resulting speculation it brings we could see 12p this week.

If there was a bid for AVCT then with its Collaborations with US Pharma Giants then the price would need to be £20 - £30 per share which for US Pharma valuations would be cheap.

GGP (Greatland Gold) also an interesting Aim listed stock with considerable upside combined with little risk.

I’m in AVCT and very happy with them , they have a lot further to go short term.

I will be investing on Monday as I can see both short and medium term upside in ORPH. It’s the management calibre that have convinced me. Especially Executive Chairman Cathal Friel who is a shrewd Irishman who has a history of successes.

Not that far off £1.50 now really, a lot nearer than we were yesterday

AVCT will be on a lot of people’s radar now.

If it can arrest the Covid-19 virus in its tracks, could it also be a treatment for the common cold ?
Makes you think.

In the short time, today could be the last chance to get in at this sort of level before the media get hold of this story .

It’s all happening at AVCT this morning as they’ve developed a treatment for Covid-19 , AVCT are a good one to retrieve your losses here.

Another buying opportunity as far as I can see , quite happy to hold and wait . As we saw the other day the sp can move up sharply just on rumour. See what will happen when we get some good news. Let TW stick to horse racing.

If the media get hold of this over the weekend , next week could be good. I don’t expect any news from the States about FDA or. CE approval until late June or July. But what news there is going to be could propel this higher by the day.

The confidence of the CEO Alastair Smith seems to suggest that the science works and FDA And CE approval Is merely a formality. If this is to be the case then £6 per share by the end of July is highly probable as the market develops through a worldwide network of distributors.